Filter by
Filter by
Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal Subcommittees.
In this guideline document, the dosimetric data and clinical evidence of PBT for esophageal cancer (EC) was summarized and evaluated. The clinical outcome data...
A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases.
This study analyzed 46 patients with 49 liver metastases treated by PBT to a total dose of 60 GyRBE in 5 fractions (BED 132 GyE) or 70 GyRBE in 10 (BED 119 GyE)...
Dose-escalated proton therapy with elective nodal irradiation and concomitant chemotherapy for unresectable, borderline resectable, or medically inoperable pancreatic cancer: a phase II trial.
Fifteen patients received proton therapy delivered 40.5 GyRBE in 18 fractions to the gross disease and elective nodal volumes followed by 22.5 GyRBE as a 10...
Identifying Individualized Risk Profiles for Radiotherapy-Induced Lymphopenia Among Patients With Esophageal Cancer Using Machine Learning.
This study analyzed the retrospective data of 746 patients with esophageal cancer treated with photons (n = 500) and protons (n = 246) to determine the...